DeepMind’s Hassabis Sees AI-Designed Drug Trials This Year (1)

Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive officer.

“We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,” Demis Hassabis, who leads both Alphabet Inc.subsidiaries, said on a panel at the World Economic Forum in Davos. “That’s the plan.”

Isomorphic Labs is working on shortening the drug discovery process from a decade or more to “weeks or months,” Hassabis said. He and another DeepMind scientist, John Jumper, shared the 2024 Nobel Prize in Chemistry with ...